Tag: ADAURA phase 3 trial

In the ADAURA phase III trial, Tagrisso from AstraZeneca showed a significant improvement in overall survival for patients with early-stage EGFR-mutated lung cancer.

Statistically significant and clinically meaningful improvements in overall survival (OS), a crucial secondary endpoint, were seen with AstraZeneca’s Tagrisso (osimertinib) compared to placebo in the adjuvant treatment of patients with early-stage (IB, II, and IIIA) epidermal growth factor receptor-mutated (EGFRm)…

Back to top

This will close in 0 seconds

Registration Form


This will close in 0 seconds